Literature DB >> 28508514

Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study.

X Moisset1,2, G Bommelaer3,4, M Boube3,4, L Ouchchane5,6, M Goutte3,4, M Dapoigny3,4, R Dallel1,7, A Guttmann5,6, P Clavelou1,2, A Buisson3,4.   

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD) are systemic, chronic inflammatory conditions that predominately affect the gastrointestinal tract and can induce abdominal pain. Besides, many IBD patients complain about headaches in daily practice. The objective was to assess the prevalence of headaches, including migraines and pain with neuropathic characteristics (NC), in IBD patients compared to historical controls from the general population.
METHODS: Overall, 203 consecutive tertiary-care centre patients completed validated self-administered questionnaires and benefitted from a clinical evaluation performed by an IBD physician at the same time.
RESULTS: In our cohort, 75% of the patients experienced pain in the previous 3 months. Migraine prevalence was two-fold higher in IBD patients compared to the general population (41% vs. 21.3%, p < 0.001). Migraine was associated with a younger age, female gender and higher depression scores. Although migraine impact was very important for 30% of the patients (61/203), specific acute therapeutics were prescribed in only 22% of cases (18/83). Chronic pain with NC was more frequent than in the general population (11.3% vs. 6.9%, p = 0.012) and was strongly associated with the presence of extra-intestinal manifestations (p < 0.001). Abdominal pain concerned 19% of the patients during the previous week and was, as expected, associated with disease activity.
CONCLUSIONS: Migraine prevalence is strongly increased in IBD patients followed in tertiary care. A systematic screening for migraine should be done by IBD physicians in daily practice to provide adequate therapeutics. Further studies are needed to confirm whether migraine should be classified as IBD extra-intestinal manifestations. SIGNIFICANCE: Migraine prevalence was two-fold higher in IBD patients compared to the general population, was generally poorly treated and a systematic screening for migraine should be done by IBD physicians in daily practice to provide adequate therapeutics.
© 2017 European Pain Federation - EFIC®.

Entities:  

Mesh:

Year:  2017        PMID: 28508514     DOI: 10.1002/ejp.1056

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  10 in total

Review 1.  Co-occurrence of pain syndromes.

Authors:  Giannapia Affaitati; Raffaele Costantini; Claudio Tana; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Neural Transm (Vienna)       Date:  2019-11-29       Impact factor: 3.575

2.  The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.

Authors:  Yong Liu; Fang Xu; Anne G Wheaton; Kurt J Greenlund; Craig W Thomas
Journal:  Headache       Date:  2021-03-23       Impact factor: 5.311

3.  Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome.

Authors:  Yangzhi Xie; Guijuan Zhou; Yan Xu; Bing He; Yilin Wang; Rundong Ma; Yunqian Chang; Duanqun He; Chenlin Xu; Zijian Xiao
Journal:  Pain Res Manag       Date:  2019-08-21       Impact factor: 3.037

4.  Basic and Clinical Advances in the Diagnosis and Management of Migraine.

Authors:  Xiaolei Shi; Wei Di; Aneta Wieczorek
Journal:  Pain Res Manag       Date:  2020-03-12       Impact factor: 3.037

5.  Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare.

Authors:  Minna A Korolainen; Samuli Tuominen; Samu Kurki; Mariann I Lassenius; Iiro Toppila; Timo Purmonen; Jaana Santaholma; Markku Nissilä
Journal:  J Headache Pain       Date:  2020-01-31       Impact factor: 7.277

Review 6.  Gut-brain Axis and migraine headache: a comprehensive review.

Authors:  Mahsa Arzani; Soodeh Razeghi Jahromi; Zeinab Ghorbani; Fahimeh Vahabizad; Paolo Martelletti; Amir Ghaemi; Simona Sacco; Mansoureh Togha
Journal:  J Headache Pain       Date:  2020-02-13       Impact factor: 7.277

7.  Association between Gastrointestinal Diseases and Migraine.

Authors:  Jemin Kim; Sujin Lee; Kiyon Rhew
Journal:  Int J Environ Res Public Health       Date:  2022-03-28       Impact factor: 3.390

8.  STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.

Authors:  Timothy R Smith; Paul Winner; Sheena K Aurora; Maria Jeleva; Jasna Hocevar-Trnka; Stephen B Shrewsbury
Journal:  Headache       Date:  2021-08-07       Impact factor: 5.311

9.  Migraine and gastrointestinal disorders in middle and old age: A UK Biobank study.

Authors:  Nike Zoe Welander; Gaia Olivo; Claudia Pisanu; Gull Rukh; Helgi Birgir Schiöth; Jessica Mwinyi
Journal:  Brain Behav       Date:  2021-07-21       Impact factor: 3.405

Review 10.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.